We are live on ! Find out more
Jacobs Levy Equity Management

Jacobs Levy Equity Management Portfolio holdings

AUM $23.8B
1-Year Est. Return 25.4%
This Fund
S&P 500
This Quarter Est. Return
+8.56%
1 Year Est. Return
+25.4%
3 Year Est. Return
+87.35%
5 Year Est. Return
+125.75%
10 Year Est. Return
+515.94%
AUM
$14.8B
AUM Growth
+$1.79B
Cap. Flow
+$849M
Cap. Flow %
5.76%
Top 10 Hldgs %
16.89%
Holding
1,178
New
178
Increased
473
Reduced
324
Closed
161

Top Sells

Rank Stock Value
1
QCOM icon
Qualcomm
QCOM
+$98.3M
2
TGT icon
Target
TGT
+$86.8M
3
OXY icon
Occidental Petroleum
OXY
+$74.7M
4
SYF icon
Synchrony
SYF
+$61.6M
5
ICE icon
Intercontinental Exchange
ICE
+$57.6M

Sector Composition

Rank Sector Weight
1 Technology 21.69%
2 Healthcare 13.54%
3 Financials 13.08%
4 Consumer Discretionary 12.97%
5 Communication Services 9.97%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VRA icon
1001
Vera Bradley
VRA
$105M
$154K ﹤0.01%
12,395
-188,448
-94% -$2.15M
PCTI
1002
DELISTED
PCTEL, Inc. Common Stock
PCTI
$152K ﹤0.01%
23,272
-10,607
-31% -$71.1K
CFB
1003
DELISTED
CrossFirst Bankshares, Inc. Common Stock
CFB
$148K ﹤0.01%
+10,759
New +$155K
FULC icon
1004
Fulcrum Therapeutics
FULC
$248M
$145K ﹤0.01%
+13,789
New +$139K
LBC
1005
DELISTED
Luther Burbank Corporation Common Stock
LBC
$144K ﹤0.01%
+12,109
New +$143K
ALTG icon
1006
Alta Equipment Group
ALTG
$210M
$135K ﹤0.01%
+10,143
New +$139K
RTL
1007
DELISTED
The Necessity Retail REIT, Inc. Class A Common Stock
RTL
$128K ﹤0.01%
+15,119
New +$141K
DBTX
1008
DELISTED
Decibel Therapeutics, Inc. Common Stock
DBTX
$117K ﹤0.01%
+13,594
New +$120K
CRD.B icon
1009
Crawford & Co Class B
CRD.B
$493M
$115K ﹤0.01%
13,330
ELVN icon
1010
Enliven Therapeutics
ELVN
$3.78B
$109K ﹤0.01%
3,449
MNTX
1011
DELISTED
Manitex International, Inc.
MNTX
$104K ﹤0.01%
14,300
FBIO icon
1012
Fortress Biotech
FBIO
$111M
$88K ﹤0.01%
1,641
-197
-11% -$11.9K
CYPH
1013
Cypherpunk Technologies Inc
CYPH
$66.2M
$85K ﹤0.01%
5,171
-45,396
-90% -$766K
PGEN icon
1014
Precigen
PGEN
$1.93B
$74K ﹤0.01%
+11,359
New +$79.4K
PXLW icon
1015
Pixelworks
PXLW
$38.8M
$65K ﹤0.01%
1,590
-16,711
-91% -$656K
MTCR
1016
DELISTED
Metacrine, Inc. Common Stock
MTCR
$54K ﹤0.01%
14,284
-1,072
-7% -$4.43K
SRGA
1017
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$23K ﹤0.01%
+557
New +$28.5K
ACAD icon
1018
Acadia Pharmaceuticals
ACAD
$4.25B
-18,845
Closed -$486K
ACGL icon
1019
Arch Capital
ACGL
$36.1B
-56,181
Closed -$2.16M
ADC icon
1020
Agree Realty
ADC
$9.68B
-15,997
Closed -$1.08M
ADEA icon
1021
Adeia
ADEA
$2.86B
-99,754
Closed -$575K
AGEN
1022
Agenus
AGEN
$249M
-7,279
Closed -$389K
ALV icon
1023
Autoliv
ALV
$8.6B
-3,334
Closed -$309K
GOLD
1024
Gold.com Inc
GOLD
$1.14B
-112,530
Closed -$2.03M
ASPS icon
1025
Altisource Portfolio Solutions
ASPS
$65.4M
-9,101
Closed -$669K

Similar funds

Jacobs Levy Equity Management's Q2 2021 Portfolio in Review

As of Q2 2021, Jacobs Levy Equity Management held 1,178 positions worth $14.8B, up 14% from $13B the previous quarter. Its ten largest holdings account for 17% of the portfolio.

Jacobs Levy Equity Management deployed $849M of net new capital in Q2 2021, opening 178 new positions and adding to 473 existing holdings. Its largest new stake was Lam Research: 991,120 shares worth $64.5M.

By sector, the portfolio is most concentrated in Technology at 22% of assets, down from 22% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Qualcomm, an estimated $98.3M trimmed.

  • Jacobs Levy Equity Management's largest Q2 2021 buy was Lam Research: 991,120 shares worth $64.5M.
  • Jacobs Levy Equity Management added most to Vertex Pharmaceuticals in Q2 2021, an estimated $128M increase.
  • Jacobs Levy Equity Management's biggest Q2 2021 reduction was Qualcomm, cutting an estimated $98.3M.
  • Jacobs Levy Equity Management fully exited Occidental Petroleum in Q2 2021, selling an estimated $74.7M.
  • Jacobs Levy Equity Management's ten largest holdings make up 17% of its $14.8B portfolio in Q2 2021.
  • Jacobs Levy Equity Management opened 178 new positions and closed 161 in Q2 2021.
  • Jacobs Levy Equity Management's portfolio value rose 14% quarter-over-quarter to $14.8B.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2021, filed 16 Aug 2021.